Allicin-Based Transethosomal Gel: A Novel Herbal Approach for Psoriasis Treatment
DOI:
https://doi.org/10.22270/ajprd.v13i4.1604Abstract
Allicin, Garlic is the source of allicin, a bioactive organosulfur molecule that has shown strong antibacterial, anti-inflammatory, and immunomodulatory properties, making it a possible topical treatment for psoriasis. However, because of its limited skin penetration and poor aqueous stability, its therapeutic value is limited. Highly flexible lipid vesicles called transethosomes, which are made of phospholipids, ethanol, and edge activators like sodium cholate, have become sophisticated nanocarrier systems that can improve the transport of drugs through the skin.In this review, the development and usage of transethosomal gels loaded with allicin as a new psoriasis treatment strategy is discussed. The article discusses important formulation parameters, physicochemical characteristics, preparation methods, and advantages over traditional delivery methods. Transethosomal systems have been shown to improve drug entrapment, extend release profiles, increase skin permeability, and improve therapeutic effects throughout the body of current literature. These characteristics highlight how transethosomal gels laden with allicin may help develop herbal-based topical treatments for inflammatory skin conditions like psoriasis.
Downloads
References
Bayan L, Koulivand PH, Gorji A. Garlic: a review of potential therapeutic effects. Avicenna J Phytomed. 2014;4(1):1–14.
Ankri S, Mirelman D. Antimicrobial properties of allicin from garlic. Microbes Infect. 1999;1(2):125–129.
Lawson LD, Wang ZJ. Allicin and allicin-derived garlic compounds: chemistry and biological properties. BioFactors. 1998;10(2-3):241–255.
Elsayed MM, Abdallah OY, Naggar VF. Lipid vesicles for skin delivery of drugs: reviewing three decades of research. Int J Pharm. 2007;332(1-2):1–16.
Manca ML, Manconi M, Caddeo C, et al. Innovative nanocarriers to improve skin delivery of drugs with antioxidant and anti-inflammatory activity. Curr Med Chem. 2021;28(2):233–252.
Singh M, Tiwari R, Mehta A. Herbal nanocarriers for dermal drug delivery: an overview. Int J Pharm Investig. 2020;10(2):85–92.
Griffiths CEM, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271.
Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.
Nickoloff BJ, Qin JZ, Nestle FO. Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol. 2007;33(1-2):45–56.
Lowes MA, Suarez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227–255.
Schön MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352(18):1899–1912.
Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol. 2007;25(6):535–546.
Tervaert WC, Steijlen PM. The role of streptococcal throat infection in the development of psoriasis. Br J Dermatol. 2001;145(6):938–944.
Kong HH, Segre JA. Skin microbiome: looking back to move forward. J Invest Dermatol. 2012;132(3 Pt 2):933–939.
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385.
Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cardiovascular disease and psoriasis: novel insights and future directions. Am J Med. 2011;124(12):e43–e53.
Russo PA, Ilchef R, Cooper AJ. Psychiatric morbidity in psoriasis: a review. Australas J Dermatol. 2004;45(3):155–159.
Gudjonsson JE, Thorarinsson AM, Sigurgeirsson B, Kristinsson KG, Valdimarsson H. Streptococcal throat infections and exacerbation of chronic plaque psoriasis. Br J Dermatol. 2003;149(3):530–534.
Takahashi T, et al. Staphylococcus aureus colonization enhances psoriatic skin inflammation. Br J Dermatol. 2020;182(5):1215–1223.
Fry L, Baker BS. Triggering psoriasis: the role of infections and medications. Clin Dermatol. 2007;25(6):606–615.
Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866–873.
Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways. Nat Genet. 2009;41(2):199–204.
Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129(6):1339–1350.
Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014;71(1):141–150.
Elder JT, Bruce AT, Gudjonsson JE, et al. Molecular dissection of psoriasis: integrating genomics and immunology. J Invest Dermatol. 2010;130(5):1213–1226.
Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, et al. Increased microvascular density and VEGF expression in psoriasis. J Invest Dermatol. 1994;103(4):534–537.
Alekseyenko AV, Perez-Perez GI, De Souza A, Strober B, Gao Z, Bihan M, et al. Community differentiation of the cutaneous microbiota in psoriasis. Microbiome. 2013;1(1):31.
Mehta H, Mashiko S, Anguera MC. Targeting cytokines in psoriasis: IL-17 and IL-23 inhibitors. Semin Cutan Med Surg. 2018;37(3):134–142.
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385.
Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–212.
Christophers E. Psoriasis—epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26(4):314–320.
Mease PJ. Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis. 2011;70(Suppl 1):i77–i84.
World Health Organization. Global report on psoriasis. Geneva: WHO Press; 2016.
Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–1960.
World Health Organization. Global report on psoriasis. Geneva: WHO Press; 2016.
Greb JE, Goldminz AM, Elder JT, Lebwohl MG, Gladman DD, Wu JJ, et al. Psoriasis. J Am Acad Dermatol. 2016;74(5):998–1013.
International Federation of Psoriasis Associations (IFPA). Global Psoriasis Coalition Initiatives. [Internet]
Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. J Am Acad Dermatol. 2011;65(1):137–174.
Elsayed MM, Abdallah OY, Naggar VF, Khalafallah NM. Lipid vesicles for skin delivery of drugs: reviewing three decades of research. Int J Pharm. 2007;332(1-2):1–16.
Gordon KB, Armstrong AW, Han C, et al. Efficacy of IL-23 and IL-17 inhibitors in psoriasis: a systematic review. JAMA Dermatol. 2019;155(5):566–577.
Schaarschmidt ML, Herr R, Gutknecht M, et al. Personalized medicine in psoriasis: where do we stand? Exp Dermatol. 2020;29(3):221–229.
Bayan L, Koulivand PH, Gorji A. Garlic: a review of potential therapeutic effects. Avicenna J Phytomed. 2014;4(1):1–14.
Armstrong AW, Chambers CJ, Maverakis E, et al. Telemedicine and teledermatology in psoriasis: a review. Br J Dermatol. 2012;167(6):1223–1228.
Kimball AB, Bagel J, Bissonnette R, et al. Addressing the unmet needs in the management of psoriasis with the treat-to-target strategy. J Dermatolog Treat. 2014;25(6):479–488.
Lebwohl MG. Psoriasis. Lancet. 2003;361(9364):1197–1204.
Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271.
Weedon D. Skin Pathology. 3rd ed. Churchill Livingstone Elsevier; 2010.
Fredriksson T, Pettersson U. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 1978;157(4):238–244.
Errichetti E, Stinco G. Dermoscopy in general dermatology: a practical overview. Dermatol Ther (Heidelb). 2016;6(4):471–507.
Ritchlin CT, Colbert RA, Gladman DD. Diagnosis and management of psoriatic arthritis: a review. JAMA. 2021;326(10):958–971.51.
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385.
Dogra S, Mahajan R. Psoriasis: epidemiology, clinical features, comorbidities, and clinical scoring. Indian Dermatol Online J. 2016;7(6):471–480.
Mason AR, Mason J, Cork M, Dooley G, Edwards G. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2013;(3):CD005028.
Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH. Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses.
Br J Dermatol. 2013;168(5):954–967.55.
Raza K, Singh B, et al. Emerging trends and advances in transdermal drug delivery. J Control Release. 2023;355:127–145.
Choudhury H, Pandey M, Chin PX, et al. Silver nanoparticles: advanced and promising technology in herbal medicine. J Adv Res. 2021;28:1–17.57. Aithal S, Udupa N.
Transethosomes and Ethosomes: promising vesicular carriers for transdermal delivery. Int J Drug Dev Res. 2020;12(1):1–7.
Moin A, et al. UV-spectrophotometric method for estimation of allicin in herbal nanoformulations. J Appl Pharm Sci. 2023;13(4):123–129.59.
Jangde R, Rai AK. Development and evaluation of topical herbal gel for anti-inflammatory activity. Pharmacogn J. 2020;12(2):332–336.
Sharma G, et al. Phospholipid-based vesicles: an ideal carrier for herbal actives. Int J Pharm Investig. 2021;11(1):12–19.
El-Nabarawi MA, et al. Elastic vesicles loaded with herbal agents: formulation and skin penetration potential. Drug Dev Ind Pharm. 2023;49(4):561–572.
. Sawant R, et al. Allicin-loaded nanoformulations: a review on potential in skin disorders. Phytother Res. 2022;36(5):2307–2319.63. Arora D, et al. Topical gels: a comprehensive review on formulation and evaluation. Curr Drug Deliv. 2020;17(3):223–234.
Chavda VP, et al. Role of PEG-based polymers in drug delivery systems: a review. Polym Bull. 2023;80(5):5277–5294.
Goyal AK, Rath G. pH modifiers in topical formulations: balancing skin compatibility and stability. Recent Pat Drug Deliv Formul. 2021;15(1):34–40.
Algahtani MS, et al. Role of ethanol in skin penetration enhancement: benefits and safety. Pharmaceutics. 2022;14(1):119.
Nayak D, et al. Role of water content and hydration in nano-vesicular systems for dermal delivery. Nanomedicine (Lond). 2021;16(2):109–123.
Jain S, et al. Ethosomes and transethosomes: innovative vesicular systems for effective dermal delivery. Drug Dev Ind Pharm. 2021;47(3):413–422.
Manca ML, et al. Transethosomes for skin delivery of antioxidants: formulation and evaluation. Pharmaceutics. 2020;12(8):742.
Elsayed MM. Lipid vesicles for topical and transdermal drug delivery: mechanisms and applications. Adv Drug Deliv Rev. 2022;189:114453.
Patel MR, et al. Herbal nanocarriers: a step toward improved stability of bioactives. Front Pharmacol. 2023;14:1123127.
Thakur N, et al. Evaluation of physicochemical parameters in topical herbal gels: standard approaches. J Drug Deliv Ther. 2021;11(1):156–161.
Sahoo SK, et al. Quality assessment of topical herbal formulations: a review. Asian J Pharm Sci. 2022;17(1):125–135.
Kaur IP, et al. Herbal topical formulations for inflammatory skin conditions: challenges and advances. J Ethnopharmacol. 2021;268:113578.
Patel MR, Sawant KK. Nanocarrier-based delivery of herbal anti-psoriatic agents: recent progress. Expert Opin Drug Deliv. 2022;19(4):465
US Patent: US20200234789A1. Garlic-derived allicin nanocarriers for topical skin therapy.
Lin Y, Wang C, Hu X, et al. Clinical evaluation of allicin-loaded nanogel in mild-to-moderate psoriasis: a randomized trial. J Dermatol Treat. 2023;34(2):312–318.
Hassan A, Khan A, Kumar R, et al. Advances in herbal nanocarriers for skin diseases: focus on phytochemical stability. Phytother Res. 2022;36(7):2951–2964.
Kalariya NM, et al. Garlic (Allium sativum L.): A potential plant for the treatment of psoriasis. J Herb Med. 2020;22:100345.
Rai VK, Mishra N, Yadav KS, Yadav NP. Nanoemulsion as a potential platform for improving the bioavailability of poorly water-soluble drugs. Pharm Nanotechnol. 2018;6(1):29–47.
Godfrey A, Gupta A, Sharma A. Vesicular systems for dermal drug delivery: a comparative review. J Drug Deliv Sci Technol. 2021;64:102620.
Mohammed MA, Syed FA, Mahmoud EA. Transethosomes: a novel vesicular carrier for enhanced skin delivery. Saudi Pharm J. 2020;28(8):999–1011.
Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MN. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine. J Pharm Sci. 2009;98(6):2037–2046.
Raza K, Singh B, et al. Topical delivery of herbal actives via lipid-based nanocarriers: current trends and future perspectives. Drug Deliv Transl Res. 2021;11(3):898–915.
Pandey A, Mishra AK, Mishra P, Dubey P. Topical nanocarriers for management of skin disorders. Curr Nanomed. 2021;11(3):231–245.
Nair AB, Shah J, Al-Dhubiab BE, et al. Nanocarriers for topical delivery of herbal drugs. Curr Drug Metab. 2020;21(6):438–448.
Kharwade RS, More S, Shaikh K, et al. Herbal nano-formulations for anti-inflammatory and skin disorders: a review. J Drug Deliv Sci Technol. 2021;66:102824.
Jangde R, Rai AK. Development and evaluation of herbal gel containing allicin for anti-inflammatory activity. Pharmacogn J. 2020;12(2):332–336.
Sethi R, et al. Transethosomes: a promising tool for transdermal drug delivery. Int J Pharm Sci Res. 2021;12(8):4158–4168.
Singh N, et al. Emerging applications of lipid-based nanocarriers in psoriasis treatment. J Drug Deliv Sci Technol. 2022;70:103243.
Moin A, et al. Analytical methods for allicin determination in garlic formulations: an updated review. J Chromatogr Sci. 2022;60(7):577–587.
Verma P, Pathak K. Therapeutic and cosmeceutical potential of ethosomes: an overview. J Adv Pharm Technol Res. 2010;1(3):274–282.
Asad MI, et al. Herbal transethosomes for topical delivery: current trends and advancements. Curr Pharm Biotechnol. 2021;22(7):957–965.
Bhatia D, et al. Nano-vesicular systems in dermal delivery: current status and future perspectives. J Control Release. 2022;341:588–608.
Nasr M, et al. Vesicular carriers for topical delivery of natural products: current trends and future prospects. Expert Opin Drug Deliv. 2021;18(9):1261–1276.
Abd E, et al. Skin delivery of allicin via ethosomal vesicles: preparation, characterization, and antibacterial activity. Pharmaceutics. 2021;13(2):242.
Agarwal T, et al. Nanostructured carriers for topical delivery of allicin: formulation and therapeutic potential. Pharm Nanotechnol. 2023;11(1):63–74.
Kharwade RS, et al. A review on herbal nanogels: recent progress and future prospects. J Drug Deliv Sci Technol. 2021;66:102828.
Gajra B, et al. Nanovesicular systems for skin delivery of bioactives: recent trends and future prospects. J Pharm Investig. 2021;51(4):391–410.
Pathan IB, Setty CM. Chemical penetration enhancers for transdermal drug delivery systems. Trop J Pharm Res. 2009;8(2):173–179.
Sharma A, Garg T, Goyal AK, Rath G. Nanovesicles for topical delivery of herbal actives: current trends and future outlook. Drug Deliv Lett. 2020;10(1):1–11.
Raza K, Singh B, Lohan S, Sharma G, Negi P, Yachha Y, et al. Nanocarriers for topical delivery of anti-psoriatic agents: current scenario and future prospects. Curr Nanosci. 2021;17(3):389–397.
Badran MM, Alhakamy NA. Recent advances in transethosomes for topical delivery of anti-psoriatic agents. J Drug Deliv Sci Technol. 2022;74:103569.
Ali M, Hussain M, Haque A, Rehman NU. Anti-inflammatory and wound healing potential of allicin: a garlic-derived compound. Phytomedicine. 2021;91:153698.
El-Nabarawi MA, Khalil RM, Abdelrahman AA, El-Setouhy DA. Nanovesicular delivery of herbal compounds: enhanced dermal delivery of allicin. Pharmaceutics. 2023;15(2):297.
Lin Y, Wang C, Hu X, et al. Clinical evaluation of allicin-loaded topical nanogel in mild-to-moderate plaque psoriasis. J Dermatol Treat. 2023;34(2):312–318.
Kaur IP, Kakkar S, Nagpal M, Singh B. Herbal topical formulations for inflammatory skin conditions: challenges and advances. J Ethnopharmacol. 2021;268:113578.
Patel MR, Sawant KK. Nanocarrier-based delivery of herbal anti-psoriatic agents: recent progress. Expert Opin Drug Deliv. 2022;19(4):465–478.
US Patent: US20200234789A1. Garlic-derived allicin nanocarriers for topical skin therapy.
Lin Y, Wang C, Hu X, et al. Clinical evaluation of allicin-loaded nanogel in mild-to-moderate psoriasis: A randomized trial. J Dermatol Treat. 2023;34(2):312–318.
Hassan A, Khan A, Kumar R, et al. Advances in herbal nanocarriers for skin diseases: focus on phytochemical stability. Phytother Res. 2022;36(7):2951–2964
Published
How to Cite
Issue
Section
Copyright (c) 2025 Yogita K. Kothawade, Deepak Sonawane, Yogesh Sharma
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.